FY2025 EPS Estimates for Tilray Raised by Atb Cap Markets

Tilray Inc (NASDAQ:TLRY - Free Report) - Investment analysts at Atb Cap Markets upped their FY2025 earnings per share (EPS) estimates for shares of Tilray in a report issued on Monday, December 16th. Atb Cap Markets analyst F. Gomes now expects that the company will earn ($0.13) per share for the year, up from their previous forecast of ($0.14). The consensus estimate for Tilray's current full-year earnings is ($0.14) per share. Atb Cap Markets also issued estimates for Tilray's FY2026 earnings at ($0.11) EPS, FY2027 earnings at ($0.04) EPS and FY2029 earnings at $0.05 EPS.

Separately, Roth Mkm lowered their target price on Tilray from $2.00 to $1.75 and set a "neutral" rating on the stock in a research report on Friday, October 11th.

Tilray Stock Performance

Shares of Tilray stock remained flat at $1.16 on Thursday. 25,338,252 shares of the stock traded hands, compared to its average volume of 25,841,539. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.47 and a quick ratio of 1.57. The company has a market capitalization of $1.05 billion, a PE ratio of -4.30 and a beta of 2.08. Tilray has a 1-year low of $1.15 and a 1-year high of $2.97. The firm has a 50-day moving average of $1.45 and a 200-day moving average of $1.66.

Tilray (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.04). Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The business had revenue of $200.00 million during the quarter, compared to the consensus estimate of $218.70 million. During the same period in the previous year, the company posted ($0.10) EPS. The business's quarterly revenue was up 13.0% compared to the same quarter last year.

Insider Buying and Selling

In related news, CFO Carl A. Merton acquired 26,000 shares of the business's stock in a transaction on Friday, November 15th. The stock was acquired at an average cost of $1.36 per share, with a total value of $35,360.00. Following the acquisition, the chief financial officer now directly owns 26,000 shares in the company, valued at $35,360. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.87% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tilray

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Montreal Can boosted its holdings in shares of Tilray by 0.3% during the 3rd quarter. Bank of Montreal Can now owns 2,176,506 shares of the company's stock valued at $3,787,000 after purchasing an additional 7,406 shares during the last quarter. State Street Corp lifted its position in shares of Tilray by 4.7% in the third quarter. State Street Corp now owns 1,961,338 shares of the company's stock worth $3,452,000 after buying an additional 88,079 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Tilray by 1,314.1% during the third quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company's stock valued at $3,202,000 after buying an additional 1,690,827 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Tilray by 6.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,677,899 shares of the company's stock valued at $2,953,000 after buying an additional 107,530 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Tilray by 2.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,487,500 shares of the company's stock valued at $2,617,000 after buying an additional 37,300 shares in the last quarter. Institutional investors own 9.35% of the company's stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.